This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
Saffron exerts its antidepressant effects primarily through the modulation of brain chemistry. Its active compounds, specifically crocin and safranal, function as serotonin reuptake inhibitors, increasing the availability of serotonin, dopamine, and norepinephrine in the synaptic cleft. Additionally, these compounds offer neuroprotective antioxidant benefits. Evidence Level B clinical trials suggest this mechanism makes saffron comparable to standard antidepressant medications like fluoxetine for mild to moderate depression.
Can I take saffron with antidepressants or blood thinners?
Caution is strongly advised when combining saffron with prescription medications. Because saffron increases serotonin levels, taking it concurrently with SSRIs or MAOIs may increase the risk of serotonin syndrome. Furthermore, saffron possesses mild anticoagulant properties, meaning it may enhance the effects of blood-thinning medications like warfarin or aspirin, increasing the risk of bleeding. Always consult a physician before adding saffron to a regimen involving these drugs.
What is the recommended daily dosage of saffron for depression?
The standard therapeutic dosage for depression in adults is 15 to 30 mg of standardized saffron extract daily. Clinical trials supporting this dosage (Evidence Level B) typically divide the intake into two doses, such as 15 mg twice daily. It is critical not to exceed 5 grams (5,000 mg) in a single dose, as this level is associated with acute toxicity and severe adverse reactions.
Is saffron safe to take during pregnancy?
Saffron is considered unsafe for medicinal use during pregnancy. High doses possess abortifacient properties, meaning they can stimulate uterine contractions and potentially induce miscarriage or premature labor. While trace amounts used as a culinary spice in food are generally recognized as safe, pregnant women should strictly avoid saffron supplements or extracts. Due to insufficient safety data, breastfeeding women are also advised to avoid medicinal doses.
What are the common side effects of taking saffron supplements?
When taken at recommended dosages, saffron is generally well-tolerated, though some users report mild side effects including dry mouth, nausea, dizziness, and headache. At very high doses, toxicity can occur, resulting in severe symptoms such as vomiting, anxiety, low blood pressure, and bleeding issues. Individuals with bipolar disorder should avoid saffron, as it may trigger manic episodes.
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Saffron (Crocus sativus) is a medicinal plant and spice with documented antidepressant, neuroprotective, and antioxidant properties [PMID:35276955, PMID:30568374].
Background
Saffron is derived from the dried stigmas of the Crocus sativus L. flower, a perennial herb originally cultivated in the East, Middle East, and Mediterranean countries [PMID:35276955, PMID:30568374, PMID:39064764].
Traditional uses
Traditionally used as a spice, coloring agent, and medicinal herb to promote blood circulation, remove blood stasis, cool and detoxify blood, relieve depression, and calm the mind [PMID:37114174, PMID:34544335]. Historical texts such as Razi's Al-Hawi mention its use as a diuretic, analgesic, anti-inflammatory, hepatoprotective, appetite suppressant, hypnotic, antidepressant, and bronchodilator [PMID:26877844].
Active compounds
The primary bioactive compounds are carotenoids including crocins and crocetin, as well as picrocrocin and safranal [PMID:35276955, PMID:30568374, PMID:37675158]. Other components include anthocyanins, flavonoids, and terpenoids [PMID:34544335].
Mechanism of action
Saffron exerts effects through antioxidant, anti-inflammatory, and neuroprotective activities [PMID:35276955, PMID:35911474]. Antidepressant mechanisms include neurotransmitter regulation, inhibition of monoamine oxidase type A and B, inhibition of monoamine reuptake, N-methyl-d-aspartate antagonism, and improvement of brain-derived neurotrophic factor signaling [PMID:39351321, PMID:35408474]. It also interacts with the Nrf2 signaling pathway to combat oxidative stress and inflammation [PMID:36033950].
Clinical evidence
Evidence AMajor Depression
Saffron was confirmed to be effective for the treatment of major depression, showing large treatment effects in placebo-comparison trials and comparable effectiveness to standard medications for mild to moderate depression [PMID:25384672, PMID:39351321, PMID:40416274].
Evidence AADHD
Saffron demonstrates promise in improving ADHD symptoms as either a single therapy or an adjuvant to methylphenidate (MPH) [PMID:37864351].
Clinical trials demonstrated saffron was more effective than placebo and as effective as donepezil in treating Alzheimer's disease [PMID:24848002]. A systematic review of RCTs found it well-tolerated in patients with MCI/AD [PMID:32445136].
Evidence BSubclinical Depressive Symptoms
A randomized, double-blind, placebo-controlled trial examined 28 mg daily of saffron extract (Affron) for mood and sleep in adults [PMID:40414301].
Safety & adverse effects
Saffron is generally reported to have an acceptable safety profile and lower incidence of side effects compared to conventional drugs [PMID:37864351, PMID:39351321]. In vitro LD50 is 200 mg/ml and in animal studies it is 20.7 g/kg [PMID:26468457].
Dosage & administration
Clinical trials have utilized dosages such as 20-30 mg/day for ADHD in children [PMID:30741567] and 28-30 mg/day for depression in adults [PMID:40414301, PMID:40416274]. No PubMed data available. Consult a healthcare provider.
Evidence summary
The evidence for saffron is strongest (Level A) for the treatment of depression and cognitive impairment due to multiple systematic reviews and meta-analyses of RCTs. Evidence for ADHD is promising based on a systematic review. Other applications (diabetes, cancer, ocular diseases) are primarily supported by reviews of preclinical or limited clinical data.
PubMed sources
1.PMID: 37864351 (2024) — The Effects of Crocus sativus (Saffron) on ADHD: A Systematic Review. · Journal of attention disorders
2.PMID: 35276955 (2022) — Saffron (Crocus sativus L.): A Source of Nutrients for Health and for the Treatment of Neuropsychiatric and Age-Related Diseases. · Nutrients
3.PMID: 25384672 (2014) — Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. · Human psychopharmacology
4.PMID: 38424688 (2024) — New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms. · Phytotherapy research : PTR
5.PMID: 40414301 (2025) — An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial.
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
6.PMID: 39351321 (2024) — Exploring the Potential of Saffron as a Therapeutic Agent in Depression Treatment: A Comparative Review. · The Yale journal of biology and medicine
7.PMID: 30741567 (2019) — Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. · Journal of child and adolescent psychopharmacology
8.PMID: 39507811 (2024) — Crocus sativus (saffron) and age-related macular degeneration. · Medical hypothesis, discovery & innovation ophthalmology journal
9.PMID: 37073363 (2023) — Analytical review of Tiryāq-i-Wabāī - A Unani panacea for the control of COVID-19. · Journal of herbal medicine
10.PMID: 30568374 (2018) — Saffron (Crocus sativus L.): As an Antidepressant. · Journal of pharmacy & bioallied sciences
11.PMID: 35911474 (2022) — A review of the anti-diabetic potential of saffron. · Nutrition and metabolic insights
12.PMID: 26877844 (2015) — Razi's Al-Hawi and saffron (Crocus sativus): a review. · Iranian journal of basic medical sciences
13.PMID: 39064764 (2024) — Saffron (Crocus sativus L.) and Its By-Products: Healthy Effects in Internal Medicine. · Nutrients
14.PMID: 34544335 (2021) — Dermoprotective Effects of Saffron: A Mini Review. · Current pharmaceutical design
15.PMID: 30483381 (2018) — Saffron (Crocus sativus) petal as a new pharmacological target: a review. · Iranian journal of basic medical sciences
16.PMID: 26468457 (2015) — The effects of Crocus sativus (saffron) and its constituents on nervous system: A review. · Avicenna journal of phytomedicine
17.PMID: 24848002 (2015) — Clinical Applications of Saffron (Crocus sativus) and its Constituents: A Review. · Drug research
18.PMID: 37528638 (2023) — Saffron (Crocus sativus) and its constituents for pain management: A review of current evidence. · Phytotherapy research : PTR
19.PMID: 40416274 (2025) — From Mood to Memory: Unlocking Saffron's Potential in Brain Health. · Cureus
20.PMID: 26151016 (2015) — Crocus sativus L. (saffron) for cancer chemoprevention: A mini review. · Journal of traditional and complementary medicine
21.PMID: 37114174 (2023) — Active constituents of saffron (Crocus sativus L.) and their prospects in treating neurodegenerative diseases (Review). · Experimental and therapeutic medicine
22.PMID: 27403251 (2016) — Therapeutic effects of saffron (Crocus sativus L.) in digestive disorders: a review. · Iranian journal of basic medical sciences
23.PMID: 33441068 (2021) — Crocus Sativus L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment. · Current neuropharmacology
24.PMID: 35408474 (2022) — Anti-Depressant Properties of Crocin Molecules in Saffron. · Molecules (Basel, Switzerland)
25.PMID: 32445136 (2020) — Effects of saffron (Crocus sativus L.) on cognitive function. A systematic review of RCTs. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
26.PMID: 33653190 (2022) — Saffron anti-metastatic properties, ancient spice novel application. · Critical reviews in food science and nutrition
27.PMID: 37587313 (2023) — Detection of botanical adulterants in saffron powder. · Analytical and bioanalytical chemistry
28.PMID: 37675158 (2023) — Phytochemistry, quality control and medicinal uses of Saffron (Crocus sativus L.): an updated review. · Journal of medicine and life
29.PMID: 36033950 (2022) — Interaction of saffron and its constituents with Nrf2 signaling pathway: A review. · Iranian journal of basic medical sciences
30.PMID: 31997799 (2020) — Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases. · Neural regeneration research